Ping An Healthcare and Technology Company Limited

This note reviews Ping An Good Doctor’s 2025 annual results and Q1 2026, emphasizing 13.7% year-on-year revenue growth to RMB 5.47 billion, a 161.3% surge in adjusted net profit, and continued margin expansion driven by higher corporate health management mix and AI-led cost restructuring. It maintains a Buy rating with PS-based valuation (5x 2026E sales, target price around HKD 16.01) and flags regulatory changes in internet healthcare, customer retention/ARPU risks, and uncertainty around future AI iterations and applications.

GF Securities’ research note highlights rapid 2025 revenue growth of 13.7% to RMB 5.47 billion, gross margin expansion to 32.4%, and a 161% jump in adjusted net profit, driven by strong enterprise health management and commercial insurance collaboration. Applying a 5x 2026E PS multiple, it sets fair value at HKD 16.46 per share, reiterates a Buy rating, and cites risks around weaker-than-expected F/B-end customer acquisition and retention as well as potential cost pressures despite AI-driven efficiency gains.

BofA Securities’ report projects 2025 revenue rising 14% year-on-year to RMB 5.5 billion and adjusted net profit up 72% to RMB 260 million, reflecting strong growth in corporate-end business and stable financial-end operations. Despite expecting margin expansion and better cost efficiency, it maintains an Underperform rating with a target price raised from HKD 7 to HKD 8.3, citing relatively slower growth and profitability versus peers and the need to balance AI investment with sustainable returns.

A UOB Kay Hian sector report summarized here forecasts Ping An Good Doctor’s adjusted net profit to grow at a 56% CAGR from 2025–2027 alongside roughly 16% revenue CAGR, supported by strong 9M25 performance (14% revenue growth and 46% adjusted net profit growth) and expanding AI integration in healthcare services. The outlook is positive on policy support for online consultations and the structural growth of AI-enabled healthcare, while implicit risks include execution on growth assumptions, regulatory evolution in online medical services, and competition in digital health platforms.

Citi’s research note highlights H1 2025 revenue of RMB 2.5 billion (up 19.5% year-on-year) and a 136.8% jump in adjusted net profit to RMB 134 million, attributing stock strength to advances in medical AI and an improved profit outlook. It raises the target price from HKD 10 to HKD 20 and reiterates an “outperform the market” stance, while noting that the thesis depends on sustained AI-driven healthcare adoption, robust commercial health insurance growth, and successful execution on margin and cash-flow assumptions.

This in-depth Longbridge analysis dissects Ping An Good Doctor’s 2025 semi-annual report, stressing 19.5% revenue growth to RMB 2.5 billion, strong net and adjusted net profit increases, and dual growth engines from F-end financial clients and B-end corporate health management. It presents an upbeat view on sustainable growth via AI-driven efficiency, expansion of elderly care and workplace health ecosystems, and high enterprise renewal rates, while implicitly warning that regulatory shifts, macro health-policy changes, and the scalability of AI and senior care initiatives remain key risks investors should monitor.